Want to join the conversation?
$EMN 2Q15 Call: SG&A and R&D as percentage of sales remains in lower quartile of peers reflecting focus on costs, integration and scale. Increasing resources and spending on innovation programs. Cash engine continues to generate strong cash flow with a record $450MM of free cash from 2Q15.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.